J Biol Chem 2000,275(8):5512–5520.PubMedCrossRef 77. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133–1 and CD133–2 in ovarian cancer. Int J Gynecol Cancer 2008, 18:506–514.PubMedCrossRef 78. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009,28(2):209–218.PubMedCrossRef 79. Curley MD, Therrien VA, Cummings CL,
Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R: CD133 expression defines a tumor initiating cell Panobinostat population in primary human ovarian cancer. Stem Cells 2009,27(12):2875–83.PubMed 80. Heider KH, Kuthan H, Stehle G, Munzert G: CD44v6: a target for antibody-based
cancer therapy. Cancer Immunol Immunother 2004, 53:567–579.PubMedCrossRef 81. Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J: Evaluation of characteristics of CD44 + CD117+ ovarian selleck chemical cancer stem cells in three dimensional selleckchem basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol 2013, 14:7.PubMedCrossRef 82. Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, MacLaughlin DT, Donahoe PK: Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA 2010,107(44):18874–9.PubMedCrossRef 83. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem
cells that are replicating in vivo. J Exp Med 1996, 183:1797–1806.PubMedCrossRef 84. Kvinlaug BT, Huntly BJ: Targeting cancer stem cells. Expert Opin Ther Targets 2007, 11:915–927.PubMedCrossRef 85. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama Glycogen branching enzyme A, Nakauchi H, Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240–251.PubMedCrossRef 86. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F: Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005, 11:729–737.PubMed 87. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506–513.PubMedCrossRef 88. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK: A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci 2004, 101:14228–14233.PubMedCrossRef 89.